Phase 3 N=180 Study of the Effectiveness of Cervical Ripening Balloon With and Without Oxytocin
Cervical Ripening · Induction of Labor · Multiparity
Primary: Time From Cervical Ripening to Delivery — 16.88; 13.13 hours
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=117 Losartan for Patients With COVID-19 Not Requiring Hospitalization
Corona Virus Infection · Acute Respiratory Distress Syndrome · SARS-CoV Infection
Primary: Percentage of Participants Admitted to the Hospital — 5.2; 1.7 percentage of participants
Phase 4 N=323 Golimumab (MK-8259 / SCH900259) Treatment Withdrawal in Participants With Non-radiographic Axial Spondyloarthritis (GO-BACK) (MK-8259-038)
Spondyloarthritis
Primary: Percentage of Participants Without a Disease Activity Flare During Period 2 — 84.1; 68.3; 33.9 Percentage of participants — p=<0.001
Phase 2 N=308 A Novel Regimen to Prevent Malaria and STI in Pregnant Women With HIV
HIV · Pregnancy Malaria · Sexually Transmitted Infection
Primary: Plasmodium Falciparum Peripheral Parasitemia — 8; 7 Participants
Phase 3 N=2,274 A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes
Diabetes Mellitus, Type 2
Primary: Change From Baseline in Glycated Haemoglobin (HbA1c) — -1.5; -1.2 Percentage of HbA1c — p=<0.0001
N/A N=193 Clinical Investigation of the AcrySof IQ Vivity Extended Vision Intraocular Lens (IOL)
Aphakia
Primary: Percentage of Subjects Not Bothered at All by Halos (QUVID Question 2.3) — 88.7; 58.1; 58.6 percentage of subjects
Phase 3 N=33 Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study
Hepatitis C Virus Infection
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) — 100; 96.4; 97.0 percentage of participants
Phase 2 N=7 A PK/PD Study of CM4620-IE in Patients With Acute Pancreatitis
Acute Pancreatitis
Primary: Exploratory: Percentage Change in IL-2 Production Relative to Pre-dose Values — -55.5 percentage of change in IL-2 production
Phase 2 N=25 Study to Evaluate SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status Epilepticus
Super-refractory Status Epilepticus
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 17; 6 Participants
Phase 2 N=8 Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 in Adults With Congenital Adrenal Hyperplasia
CAH - Congenital Adrenal Hyperplasia
Primary: Percent Change From Baseline to Day 14 in 17-hydroxyprogesterone (17-OHP) Morning Window Averages — -60; -58; -53; -64 Percent (%)
Phase 4 N=120 Nebulized Sub-dissociative Dose Ketamine for Treating Pain
Pain
Primary: Change in Pain Scores From Baseline to 30 Minutes — 4.0; 4.2; 4.1 units on a scale
Phase 2 N=22 Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
Multiple Myeloma
Primary: Phase I: Recommended Phase II Dose (RPh2D) — 80 mg
Phase 2 N=12 The Effect of Bariatric Surgery on Metabolism, the Metabolome and Microbiome in Patients With Type 2 Diabetes
Type 2 Diabetes Mellitus · Obesity
Primary: Fasting Glucose — 6.1; 7.23; 6.48; 5.89 mmol/l
N/A N=29 Effects of CPAP on Diet, Physical Activity, and Cardiovascular Risk
Sleep Apnea Syndromes
Primary: Fat Mass (% of Total Body Mass) — 40.0; 37.7; 38.7; 38.6 percentage of total body mass
Phase 2 N=175 (Hyoscine Butylbromide) for Abdominal Pain Associated With Cramping on Demand Basis
Abdominal Pain
Primary: Change From Baseline in Intensity of Abdominal Pain Associated With Cramping Following Treatment Based on the Numeric Pain Rating Scale (NPRS) in Episode 1 — -2.7; -3.1…